IP Library Granted Patent US 8,062,287
Granted Patent B2
US 8,062,287 · App. 12/158,059 · Granted Nov 22, 2011

Device for controlled release of chemical molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,062,287
App. No.
12/158,059
Granted
Nov 22, 2011
Kind
B2
Abstract

The invention relates to a device comprising an ingestible capsule which measures at least one body parameter and starts a drug release program upon predefined changes in the body parameter.

Claims (38)

1. A medical device for drug administration comprising:

a) a device which measures at least one body parameter of a patient for at least one measuring cycle and at least one monitoring cycle,

b) a central control unit programmed to generate a normalized curve for each of the at least one measured body parameter of the patient from measured data obtained in the at least one measuring cycle and to adjust the measured data obtained in the at least one monitoring cycle to normalize the measured data based on the normalized curve to generate normalized monitoring data, and

c) an ingestible capsule which starts releasing the drug in response to a change of at least 25%/hour on a normalized scale being observed in the normalized monitoring data for a period of at least 1 hour.

2. The device according to claim 1 , wherein the at least one body parameter includes at least one of body temperature, core body temperature, skin surface temperature, blood pressure, melatonin level, triacylglycerol level, and cortisol level.

3. The device according to claim 1 , wherein the central control unit controls the ingestible capsule to start releasing the drug during the at least one monitoring cycle in response to a change of at least 40%/hour on the normalized scale being observed in the normalized monitoring data for a period of at least 3 hours.

4. The device according to claim 1 , wherein the central control unit controls the ingestible capsule to start releasing the drug during the at least one monitoring cycle in response to the normalized monitoring data deviating from a minimum point of the normalized curve by a threshold value of at most 25%.

5. The device according to claim 1 , wherein the central control unit controls the ingestible capsule to start releasing the drug during the at least one monitoring cycle in response to the normalized monitoring data deviating from a maximum point of the normalized curve by a threshold value of at most 25%.

6. The device according to claim 1 , wherein the central control unit controls the ingestible capsule to delay releasing of the drug for at most 2 measuring and/or monitoring cycles.

7. The device according to claim 1 , wherein the central control unit controls the ingestible capsule to delay releasing of the drug for between 1 and 24 hours.

8. The device according to claim 1 , wherein the central control unit controls the ingestible capsule to stop releasing the drug after one of:

at most 30 cycles and

when the normalized monitoring data return to between at least −60% and at most 60% of the preselected point of the normalized curve.

9. The device according to claim 1 , wherein the drug is also released in response to the normalized monitoring data deviating from a preselected point on the normalized curve by more than a threshold value of at most 50% on a normalized scale.

10. A method for the controlled release of drugs from a capsule, comprising:

a) measuring at least one body parameter of a patient for at least 3 measuring cycles and at least one monitoring cycle,

b) generating a normalized curve for the measured body parameter of the patient;

c) adjusting the measured body parameter obtained in the at least one monitoring cycle to normalize the measured body parameter based on the normalized curve to generate normalized monitoring data, and

d) starting to release a drug during the at least one monitoring cycle in response to at least observing a change of at least 25% in the normalized measured body parameter for a period of one hour.

11. The method according to claim 10 , wherein the measured body parameter includes at least one of body temperature, core body temperature, skin surface temperature, blood pressure, melatonin level, triacylglycerol level, and cortisol level.

12. The method according to claim 10 , further comprising:

starting the drug release program in response to observing a change of at least 40%/hour in the normalized measured body parameter for a period of at least 3 hours.

13. The method according to claim 10 , further comprising:

starting the drug release program in response to the normalized measured body parameter deviating from a minimum point of the normalized curve by a threshold value of at most 25%.

14. The method according to claim 10 , further including:

stopping release of the drug based on a rate of change in the normalized measured body parameter.

15. The method according to claim 10 , further including:

delaying starting to release the drug by at least 1 hour.

16. The method according to claim 10 , further including:

stopping release of the drug after at most 30 cycles or when the normalized measured body parameter returns to between −60% and 60% of the preselected point on the normalized curve.

17. The method according to claim 10 , wherein the release of the drug is started in response to the normalized measured body parameter deviating from a preselected point of the normalized curve by a preselected percentage.

18. A drug administration device comprising:

an ingestible capsule;

a parameter monitor disposed in the ingestible capsule to measure at least one body parameter of a patient who has ingested the ingestible capsule;

a drug storage container disposed in the ingestible capsule which stores drugs;

a valve which is controllable to release the drugs in the drug storage container from the ingestible capsule; and

a control unit disposed in the ingestible capsule, the control unit receiving measured body parameter data from the parameter monitor, generating a normalized curve from the measured body parameter data over a plurality of monitoring cycles, normalizing the measured body parameter data, and controlling the valve to release the drugs in response at least to the normalized measured body parameter changing at a preselected rate for a preselected duration.

19. The device according to claim 18 , wherein the control unit further controls the valve to release the drugs in response to the normalized body parameter deviating from a selected point on the normalized curve by a preselected threshold value.

Assignments (9)
SECURITY INTEREST Recorded Aug 15, 2025
From: BT BIDCO, INC.
To: GLAS USA LLC
Reel/Frame 072473/0861 →
LIEN Recorded Mar 31, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO LLC
Reel/Frame 070690/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO, INC.
Reel/Frame 070688/0297 →
SECURITY INTEREST Recorded Dec 21, 2023
From: BIORA THERAPEUTICS, INC.
To: GLAS TRUST COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 066089/0235 →
CHANGE OF NAME Recorded Sep 19, 2023
From: PROGENITY, INC.
To: BIORA THERAPEUTICS, INC.
Reel/Frame 064961/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2018
From: STOCO 10 GMBH
To: PROGENITY, INC.
Reel/Frame 045831/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2017
From: MEDIMETRICS PERSONALIZED DRUG DELIVERY B.V.
To: STOCO 10 GMBH
Reel/Frame 043463/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2012
From: KONINKLIJKE PHILIPS ELECTRONICS N.V.
To: MEDIMETRICS PERSONALIZED DRUG DELIVERY B.V.
Reel/Frame 027756/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2008
From: KRIJNSEN, HENDRIKA CECILIA; LANGEREIS, GEERT; VAN BRUGGEN, MICHEL PAUL BARBARA; IORDANOV, VENTZESLAV PETROV
To: KONINKLIJKE PHILIPS ELECTRONICS N V
Reel/Frame 021116/0856 →